glp 1 agonist natural sources GLP-1 Alternatives: Supporting Metabolic Health The Multifaceted Nature of GLP-1:

Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.

Obesity and associated metabolic disorders such as type 2 diabetes mellitus and polycystic ovary syndrome are rising globally, contributing to infertility and adverse pregnancy outcomes

Approved 20 years ago as a treatment for diabetes, GLP-1 drugs have been found also to help patients significantly reduce weight

Since most glucose-dependent insulinotropic polypeptide (GIP) receptor: glucagon-like peptide- 1 receptor (GLP- 1) receptor: glucagon receptor triagonists compete in efficacy with bariatric surgery, the success of these agents in preclinical models and clinical trials suggests a bright future for multi-agonists in the treatment of metabolic diseases

These effects extend beyond weight loss, suggesting anti-inflammatory mechanisms with broad potential for managing chronic diseases.